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ACEI  = angiotensin converting enzyme inhibitor 
ARB  = angiotensin receptor blocker 
CvLPRIT = Complete versus Lesion-only PRimary PCI Trial 
IRA  = infarct-related artery 
LV  = left ventricle/ventricular 
MPS  = myocardial perfusion scintigraphy 
OMT  = optimal medical therapy 
PPCI  = primary percutaneous coronary intervention 
QCA  = quantitative coronary angiography 
STEMI  = ST-elevation myocardial infarction 
  
The Complete versus Lesion-only PRimary PCI Trial (CvLPRIT) was undertaken in seven United Kingdom 
centres.[1,2] Patients with ST-elevation myocardial infarction (STEMI) and multivessel coronary stenoses 
were randomized to primary percutaneous coronary intervention (PPCI) to the infarct-related artery 
(IRA) only, or complete revascularization. At 12 month follow-up, the rate of the combined primary 
endpoint (all-cause mortality, recurrent MI, heart failure, ischaemia-driven revascularization) was lower 
after compl ete revascularization. All surviving patients were asked to undergo myocardial perfusion 
scintigraphy (MPS) 6-8 weeks post admission. It was expected that this a priori nuclear substudy would 
provide mechanistic insights into the outcome of the main trial, and help to define the clinical role of MPS 
in the PPCI era.  
Stress-rest MPS was performed according to local departmental practice: technetium-99m-
tetrofosmin 95%, two-day protocol 84%, vasodilator stress 84%, glyceryl trinitrate at rest 59%. Blinded 
semiquantitative analysis was performed in a central core-lab (ADK), and summed scores were expressed 
as percentages of the left ventricular myocardium (%LV). Separate scores were calculated for IRA and 
non-IRA territories. Supervising physicians were blinded to the resul ts of MPS unless inducible 
hypoperfusion exceeded 20%LV (no patient), or symptoms developed within one month such that 
another ischaemia test would otherwise have been required (3 patients, all IRA-only, no significant 
inducible hypoperfusion, no further revascularization).  
Of 296 CvLPRIT patients, 205 (69%) underwent MPS as intended; they were broadly similar to 
those in the overall study cohort.[1] The vast majority were asymptomatic and on optimal medical 
therapy (OMT) at the time of MPS (Table). IRA-only patients had more extensive resting defects 
(infarction) than complete revascularization patients (Table). This was associated with a non-significant 
trend towards more extensive infarction in the territory of the index IRA rather than that of a non-IRA. 
The extent of inducible hypoperfusion (ischaemia) was small, and exceeded 10%LV in only 14 patients 
(7%). There was no difference between the IRA-only and complete revascularization groups (Table).  
Sixteen patients suffered a l ate cardiac event following MPS. No scintigraphic variabl e was 
predictive of the combined primary end-point. However, the extent of infarction was greater in patients 
suffering death, MI or heart failure than in those who had no event or a revascularization event – 23.5 
(19.1-35.3) versus 8.8 (4.4-16.2) versus  7.4 (2.9-10.3) %LV, P<0.01 – whilst resting LV ejection fraction 
was lower – 43 (30-45) versus 57 (51-62) versus 59 (46-62) %, P=0.01. The extent of inducible 
hypoperfusion was similar – 0 (0-1.5) versus 1.5 (0-4.4) versus 2.9 (0-7.4) %LV, P=0.26.  
The reduction in infarct size after complete revascularization might represent early 
improvement in collateral perfusion from treated non-IRAs to the watershed of the IRA territory. “Hard” 
cardiac events (as opposed to revascularization) occurring after MPS were associated with more 
extensive infarction and more severely impaired LV systolic function. It is therefore plausible that a small 
reduction in median infarct size explains the lower rate of early heart failure events and death seen in the 
complete revascularization arm of CvLPRIT.[1,3] Interestingly, the CvLPRIT cardiac magnetic resonance 
substudy showed no significant difference in infarct size between the randomized groups  prior to 
hospital discharge.[2] This discrepancy probably reflects differences in the substudy populations, and the 
likelihood that early imaging overestimated infarct size. 
All patients had undergone PPCI to the IRA and were receiving contemporary OMT. This may 
expl ain the limited inducible hypoperfusion seen even in the IRA-only group, and the inability of complete 
revascularization to reduce it further.[4] Therefore residual ischaemia is unlikely to be an important 
driver of further events post-PPCI for STEMI, and its suppression alone cannot explain the reduced event 
rate in the complete revascularization arm of CvLPRIT. Finally, routine ischaemia testing in asymptomatic 
patients following hospital discharge after PPCI for STEMI may have a limited yield, even in those with 
unrevascularized non-IRAs.  
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Table. Characteristics of patients in the CvLPRIT Nuclear Substudy. 
Variable IRA-only Complete p 
Number 101 104  
Clinical status at time of MPS at 6-8 weeks 
Canadian Cardiovascular Society class 0-1 87/91 (96) 96/96 (100) 0.054 
New York Heart Association class 1 78/89 (88) 84/93 (90) 0.56 
Beta-blocker 86/100 (86) 96/104 (92) 0.15 
Statin 98/100 (98) 103/104 (99) 0.62 
ACEI or ARB 95/99 (96) 99/104 (95) 0.99 
MPS variables 
Stress defect (%LV) 13.2 (7.4-19.1) 13.2 (7.4-16.2) 0.16 
Rest defect (%LV) Overall  10.3 (5.9-17.6) 8.8 (4.4-14.7) 0.049 
IRA territory  8.8 (3.3-14.0) 5.9 (2.9-11.8) 0.09 
Non-IRA territory  0 (0-4.4) 0 (0-4.0) 0.70 
Inducible hypoperfusion (%LV) 1.5 (0-4.4) 1.5 (0-5.9) 0.70 
Resting ejection fraction (%) 58 (49-62) 57 (50-64) 0.84 
Primary clinical end-points 
Early events (pre-MPS or <6 weeks) 9 (9) 1 (1) <0.01 
Late events (post-MPS or >6 weeks) All events  12 (12) 4 (4) 0.04 
Death   1 (1) 0 (0) 
Recurrent MI  1 (1) 0 (0) 
Heart failure  2 (2) 1 (1) 
Revascularization  8 (8) 3 (3) 
 
Results shown as mean (SD), median (IQR), or number of patients (%).  
ACEI – angiotensin converting enzyme inhibitor; ARB – angiotensin receptor blocker. 
 
 
